Evidence map›Paper›PMID 36071389›Full record

ArticleBMC public health2022

An overview of implementing an evidence based program to increase HPV vaccination in HIV community clinics.

Jessica Wells, James L Klosky, Yuan Liu, Theresa Wicklin Gillespie

Registry-linked trialOpen access · goldAbstract read
In one paragraph

Article in BMC public health, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05065840 (Implementing an Evidence-Based, Multilevel Intervention to Promote HPV Vaccination Among HIV Positive Adults), which is not on this map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.2field-weighted citation impact, top 49% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05065840 naactive not recruitingnot on this mapstarted 2023, after this paper: background citation

Implementing an Evidence-Based, Multilevel Intervention to Promote HPV Vaccination Among HIV Positive Adults

TypeinterventionalSponsorEmory UniversityRan2023 to 2028Enrolled267ConditionsHuman Papilloma Virus, Human Papilloma Virus VaccineArmsCDC 4 Pillars Program
3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Jessica WellsNell Hodgson Woodruff School of Nursing, Emory University, 1520 Clifton Road, NE, RM. 230, Atlanta, GA, 30324, USA. jholme3@emory.edu.ORCID 0000-0003-1995-0383
James L KloskyDepartment of Pediatrics, School of Medicine, Emory University, Atlanta, GA, USA.
Yuan LiuDepartments of Biostatistics and Bioinformatics, Emory University, Atlanta, GA, USA.
Theresa Wicklin GillespieWinship Cancer Institute, Emory University, Atlanta, GA, USA.
Emory University · US

Funding

Winship Cancer Institute Cancer Center Support GrantP30CA138292 · NCI · EMORY UNIVERSITY · PI Suresh S Ramalingam · 2009 to 2026
$47.5M
Implementing an evidence-based, multilevel intervention to promote HPV vaccination among HIV positive adultsR01NR020154 · NINR · EMORY UNIVERSITY · PI WELLS, JESSICA · 2021 to 2025
$2.0M
NCI NIH HHS P30 CA138292NINR NIH HHS R01 NR020154
6 · The paper itself

Abstract

backgroundHPV-related anal cancer occurs in excess rates among people living with HIV (PLWH) and has been increasing in incidence. The HPV vaccine is an effective and safe approach to prevent and reduce the risk of HPV-related disease. Yet, HPV vaccine programs tailored and implemented in the HIV population are lagging for this high-risk group.

methodsA pre-post intervention study design will be used to tailor, refine, and implement the 4 Pillars™ Practice Transformation Program to increase HPV vaccination among PLWH. Guided by the RE-AIM framework, the CHAMPS study will provide training and motivation to HIV providers and clinic staff to recommend and administer the HPV vaccination within three HIV clinics in Georgia. We plan to enroll 365 HIV participants to receive HPV education, resources, and reminders for HPV vaccination. Sociodemographic, HPV knowledge, and vaccine hesitancy will be assessed as mediators and moderators for HPV vaccination. The primary outcome will be measured as an increase in uptake rate in initiation of the HPV vaccine and vaccine completion (secondary outcome) compared to historical baseline vaccination rate (control). DISCUSSION: The proposed study is a novel approach to address a serious and preventable public health problem by using an efficacious, evidence-based intervention on a new target population. The findings are anticipated to have a significant impact in the field of improving cancer outcomes in a high-risk and aging HIV population.

trial registrationNCT05065840; October 4, 2021.

Indexed as

HIV InfectionsPapillomavirus InfectionsPapillomavirus VaccinesAmbulatory Care FacilitiesHumansVaccinationPapillomavirus VaccinesHIVHPV vaccinationImplementation

Identifiers

PMID36071389
PMCPMC9450352
OpenAlexW4294877231

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.